Safety Study of HBV-002 West Nile Vaccine in Healthy Adults

Inclusion Criteria: * Satisfactory medical assessment with no clinically significant and relevant abnormalities (medical history, physical examination, vital signs, ECG, clinical laboratory evaluation \[hematology, biochemistry, urinalysis\]) * Body weight must not be more than 10% below of 20% above the ideal weight for height and frame size according to the 1999 Metropolitan Life table Exclusion Criteria: * Current active infection process including URI or influenza * Positive serum test for HIV, Hepatitis B surface antigens and/or Hepatitis C antibodies * History of infection with, or serologic evidence in screening test, of prior flavivirus infection (to include viruses: West Nile, 4 dengue serotypes, yellow fever (YF), and Japanese encephalitis (JE) * Subject has resided in flavivirus (West Nile, 4 dengue serotypes, YF, and JE) endemic areas or has a history of receipt of Yellow Fever or Japanese encephalitis virus vaccines * History of alcohol or other substance abuse within 1 year of screening * Use of corticosteroids or immunosuppressive drugs within 30 days of screening (Use of topical or nasal corticosteroids are not excluded.) * Any confirmed or suspected immunosuppressive or immunodeficient condition * Administration of immunoglobulins within three months of the first vaccination or planned during the study period * Receipt of any vaccines or investigational or non-registered product other than HBV-002 within 30 days prior to screening or planned receipt throughout the study. * Receipt of another study vaccines within 30 days prior to screening * Receipt of blood products within 6 months of screening